Cervical cancer is the second most frequent
gynecological tumor worldwide. The main reason for this frequency is not
practicing adequate cytological screening. We performed a descriptive study of
patients with invasive cervical cancer treated at our center from January 2003
through December 2015. In this period, 316 patients were diagnosed with
cervical cancer. The mean age was 54.39 ± 16.20 years, with a range of 19 to 90
years and a mode of 49 years. A total of 77.8% of the patients were Spanish and
22.2% were foreign. The initial treatment was surgical in 57.9% of the patients
and radio-chemotherapy in 42.1%. The most frequent tumoral stage was IIB
followed by IB1. The most common histological type was squamous carcinoma
(61.3%), followed by adenocarcinoma (22.6%). Most of the patients, 64.2%, did
not experience a relapse and overall survival was 64.9%. Notably, 86.30% of
study subjects had not had an appropriate cervical cancer screening test.
After breast cancer, cervical cancer is the type of cancer with
the highest incidence and mortality worldwide [1]. As many as 83% of cases of
cervical cancer are diagnosed in developing countries, whereas it is less
frequent in developed countries [2]. In Europe, cervical cancer ranks fourth
among the most frequent types of cancer, and it is the seventh most common
cause of mortality [3]. Although Spain is one of the European countries with a
lowest incidence, two women die every day from cervical cancer despite the
successful screening programs in place. The primary goal of this study was to
determine the incidence, therapy, relapse rate, and mortality of patients
diagnosed with infiltrating cervical cancer treated in our hospital in the last
13 years to assess the evolution of these factors over time.
Secondary objectives included assessing the origin of referral,
tumor stage, and more frequent histological types, and determine the efficacy
of screening programs. The study was performed in the Miguel de Servet
University Hospital (HUMS), which is located in Zaragoza, the fifth largest
city of Spain. HUMS is a third-level hospital serving a population of 530,510
people. It is also the reference hospital for gynecologic oncology of the
Autonomous Community of Aragon. Aragon has a population of 1.277.471
inhabitants, which accounts for 2.85% of the Spanish population. The total
population of Zaragoza is 917,288 (71% of the population of Aragon). We
conducted a retrospective review of patients diagnosed with cervical cancer and
treated in our hospital from January 2003 to December 2015. During the study
period, a total of 316 women were diagnosed with cervical cancer.
No comments:
Post a Comment